Project Heinz Information memorandum Scan QR code
Disclaimer This Information Memorandum is issued by the Shareholders of IG Technology Ltd (“IGT” or the “Business”) on the terms set out below for the exclusive use of the persons to whom it has been issued, and their professional advisors, in connection with the proposed sale of the Business as defined in this document. The Information Memorandum is confidential and is made available strictly on the basis of your interest in a potential acquisition of IGT. The information and opinions contained in this Information Memorandum are strictly private and accordingly the contents of this Information Memorandum and any other information or opinion subsequently supplied or given in connection with the proposed sale will constitute confidential information and may not be published, produced, copied or disclosed to any person other than the professional advisors to the recipient of the Information Memorandum having a need to know and who are aware that it is confidential, nor used for any purposes other than in connection with the proposed sale. No representation or warranty, expressed or implied, is given by Praestantia Advisory, IGT, their respective advisors or any of their respective directors, employees or any other person as to the accuracy or completeness of the contents included within this Information Memorandum or the accuracy or completeness of any projections included within this Information Memorandum or of any other document or information supplied at any time in connection with the proposed sale. Neither IGT nor Praestantia Advisory nor any of their agents give any guarantees or warranties as to the statements included herein. Any purchaser must satisfy themselves as to the accuracy of the information herein and the assets available for sale. The statements contained herein must not be relied upon as statements or representations of fact. Neither IGT nor Praestantia Advisory shall be responsible for any error, omission or misstatement. Neither this Information Memorandum nor any of the information contained in it shall form the basis of any contract for the sale of the Business or any part thereof, nor does it constitute an offer or invitation to purchase or acquire any shares in the Business or any interest therein. The recipient will keep this Information Memorandum and all information subsequently supplied or given to it or its agents or professional advisors in connection with the proposed sale safe and secure so as to prevent any unauthorised person having access to it, and agrees that the information is proprietary to the Business, and it has no rights to it except as set out in this notice. 2
3 Investment highlights Selected from a competitive global field to join the prestigious Mayo Clinic & Arizona State University MedTech Accelerator Programme…and, against a strong cohort of international enterprises, proudly recognised as the Winner of the 2025 Impact Award Award winning, clinically validated and rapidly advancing • Endorsed by leading clinicians and validated through rigorous trials, Legacy IPC has progressed swiftly through clinical and regulatory milestones; unrivalled user feedback highlights its efficacy, particularly in engagement, compliance tracking and user experience • Legacy’s proven excellence, validated by multiple industry accolades, reinforces its exceptional quality and market differentiation — key drivers of sustained value creation Meeting a global unmet need • DVT impacts millions worldwide. Legacy IPC delivers proven, portable therapy for VTE — empowering hospitals and home-care providers to prevent more, treat better, and protect patients everywhere • Legacy IPC redefines intermittent pneumatic compression with a portable, wireless, and totally silent system designed for patient comfort and optimal clinical performance. App-based compliance monitoring ensures superior adherence, driving measurable improvements in outcomes Technology driven market differentiation • Whilst established competitors focus on static, hospital-based systems, Legacy delivers a SMART, totally portable, and connected IPC solution • Its combination of silent operation, reusable design, and continuous real-time data analytics positions it as a next-generation, multi-setting device…not just another hospital tool Sustainability as a strategic advantage • Healthcare providers globally face mounting pressure to cut plastic use and lower carbon emissions • Legacy IPC’s low-waste, reusable design aligns with ESG mandates and reduces total cost of ownership — giving it a tangible competitive edge in procurement and partnership decisions The Legacy IPC system has been designed using transformational technology to improve and monitor compliance to reduce the incidence of DVT and save costs and lives
4 Investment highlights Transforming healthcare with high-impact innovation: a future-proof, SaaS-enabled healthcare platform delivering sustainable growth, global scalability, and improved patient outcomes High quality, diversified revenue streams • As a SaaS / device model, Legacy generates predictable recurring income through device sales, consumables, and from Legacy Gateway’s subscription-based data package • This model enhances lifetime customer value and creates a sticky ecosystem for healthcare partners Digital health integration and data value creation • Legacy’s IoMT-enabled design uniquely connects seamlessly into digital health infrastructures, offering enhanced patient monitoring, diagnostics, and treatment • Integration with electronic health records unlocks valuable insights and data-driven partnership potential • HIPAA compliant data capture that can be easily linked to any health provider’s EHR system like EPIC or Oracle Globally disruptive and strategically relevant • As healthcare systems worldwide pursue cost-efficient, outpatient-oriented therapies, Legacy delivers a transformational value-based care solution that is simply light years ahead of anything else currently available • It empowers providers to reduce hospital stays while maintaining clinical efficacy — and therefore aligns perfectly with current healthcare transformation trends International scalability and market adjacencies • Legacy is poised for significant international expansion, with opportunities to accelerate growth in the US, establish a strong presence across Africa and the Middle East, and capture high-potential markets throughout APAC • Beyond its core healthcare applications, the potential exists for Legacy to expand into adjacent markets such as sports medicine, rehabilitation, and wellness; plus exciting new opportunities are emerging across the travel and leisure sectors
Contents 01 The opportunity 6 02 Legacy IPC system 10 03 Supply chain 17 04 Growth opportunities 19 05 Acquisition drivers 21 Appendix 1: Legacy and healthcare providers 24 Appendix 2: Florida Bill on VTEs 25 Appendix 3: Glossary 26 5 The ever-expanding integration of wireless tech, mobile apps, and cloud platforms into healthcare supports demand for connected devices like Legacy IPC
The opportunity
Purpose • Legacy IPC prioritises the needs of patients, enhances healthcare outcomes and addresses a critical worldwide healthcare need Methodology • Legacy IPC disrupts the market with an innovative product that provides more features, functionality and greater ease of use than existing propositions Vision & mission • Legacy IPC is a game changer! A reaction to the established players in the market who fail to converse with patients, clinicians and the dynamics of modern healthcare systems 7 The opportunity Ageing population, diet, lifestyle and an increasing prevalence of chronic vascular conditions like DVT, lymphoedema, and venous ulcers are raising demand for more efficacious IPC therapy Market context The problem • 10 million VTE cases globally with 600,000 deaths, which is forecast to grow by 8% by 2030 due to increased prevalence of surgery, obesity, old age • Blood clots are attributable to 10% of all hospital deaths • 60% of blood clots occur up to 90 days after discharge • Growth of VTE in China is 10 fold from 2015 -2020 • Everyone is vulnerable to VTE…children through to the elderly! • In the U.S. the annual cost to treat VTE is $7- $10Bn plus an estimated ‘societal cost’ of c. $70Bn. In the UK the annual cost is c.£1bn and Europe c.$4Bn • VTE is the most preventable cause of death within hospitals. Prevention saves health providers c.$20K for every case progressing to a pulmonary embolism • 70% of VTE cases can be avoided with the correct prophylaxis VTE prophylaxis Compression stockings Low cost…BUT • Often poorly fitted • Ineffective • Uncomfortable Anticoagulants Reduction in VTE >50%…BUT • Treatment typically 3-6 months • Numerous side effects • LMWH subcutaneous injection Mechanical SCD Reduction in VTE >50%…BUT • Low compliance <40% • Hospital use only • Limited availability Disrupting the current system Why? • The market predominantly offers old, outdated technology that ignores patient centricity and delivers sub-optimal healthcare outcomes Current evidence indicates that graduated compression sleeves are ineffective…the solution: ‘Legacy IPC’
8 The opportunity Legacy has a range of advantages in the IPC market as healthcare shifts towards digital monitoring and compliance, home-based care…and the need for connected, sustainable technologies Feature Specification USPs Silent 1-2dBA over ambient Only totally silent IPC on the market Compact 106mm x 45mm x 17mm Smallest IPC on the market Lightweight 70 grammes Lightest IPC on the market Long runtime >24hours on a single charge Only portable IPC that can run for more than 24 hours on a single charge and requires only three hours to charge Connectivity Wireless Only IPC connection to any iOS and Android device with later retrieval of data Effectiveness 45mmHg compression 45mmHg compression every minute Lifetime One year @ 18Hrs / day Shown to run continuously for three years. 1 year warranty SKUs One size fits all Availability and stock management improved Reduced cost 50% reduction Running costs e.g. compared to the Flowtron and Kendall SCD Environment 66% reduction Reduction in plastic waste e.g. compared to the Flowtron and Kendall SCD Compliance Home or Hospital Can be used in both the hospital or community care How Legacy IPC differs… Legacy IPC stands out by solving real-world problems that conventional IPC systems ignore Mechanical SCD • Static connection to a bedside pump…uncomfortable, restrictive, with the potential for falls • Noisy operation from each cycle, which impacts a patient’s ability to sleep / rest • Labour intensive and inefficient: constant removal / reapplication of limb sleeves result in a higher nurse workload • Limited number of pumps, combined with multiple sleeve sizes makes management difficult • High financial and environmental cost related to the disposal of sleeves and tubes • Patients remove limb sleeves due to excessive heat; plus tissue injuries due to excess moisture • Inability to effectively record and monitor compliance • No effective outpatient / home-care offering
9 The opportunity A highly talented management team that is dedicated to merging state-of-the-art technology with technical expertise to enhance healthcare outcomes Shareholder management team • Led by a seasoned leadership team that collectively owns over 70% of IG Technology Ltd, the Business is driven by CEO Ivan Green, CTO Dr. Stephen Ingram, and CCO Eliot Clare. Together, they bring a powerful combination of engineering expertise and medical device innovation with a passion to make a difference Ivan Green – CEO Co-founder of IG Technology Ltd, developer and manufacturer of the Legacy IPC Educated: University of London: Masters Mechanical and Electrical Engineering (1st Class), CEng Experience: Medical Device industry - 25 years globally - Orthopaedics, Wound Care, Trauma, Chronic Care, Biologics Consultant: Johnson and Johnson, Zimmer Biomet, Smith and Nephew, AK Medical, Advanced Medical Solutions and numerous healthcare focused SMEs and Clinicians Dr Stephen Ingram – CTO Co-founder of IG Technology Ltd, developer and manufacturer of the Legacy IPC Doctor of Philosophy (Ph.D.) School of Computing and Electrical Engineering University of Bradford Experience: Medical Device industry - 15 years - patient monitoring, electronic diagnostic device, hospital wireless systems and wearables Consultant: Osler Diagnostics, GE Healthcare and Philips Eliot Clare – CCO Co-founder of IG Technology Ltd, developer and manufacturer of the Legacy IPC Liverpool University: BA (Hons) in Sports Science and Geography Co-Founder of Ortho Solutions Holdings Ltd – a lower extremity, foot and ankle medical products manufacturer 25 years’ experience of the medical device industry primarily orthopaedics
Legacy IPC system
11 Legacy IPC system An innovative, tech-driven IPC system that redefines patient care through silent operation, compact design, wireless functionality, mobile app integration, intelligent data capture, and AI capability for automated analysis and smarter clinical insights A ground-breaking & highly disruptive solution for VTE prophylaxis • Legacy IPC is an FDA and SFDA approved IPC device that uses a novel patented technology, which mimics ambulation to provide portable compression for both hospital care and home use • Using this technology enables Legacy to be the smallest, lightest and only totally silent IPC device on the market, providing compression for up to 24 hours on a single charge • The Legacy IPC has demonstrated equivalence to SCD devices showing comparative venous volume total flow rates and velocities…but which has the capability to be recharged in 2-3 hours for repeated use everywhere, including X-ray, CT, OR and nuclear medicine • Wireless connectivity allows remote monitoring of multiple pumps with the status being reviewed using the Legacy App and alerting the nurse through the dedicated paging system • Compliance tracking and management of nursing teams using the automated daily reports showing compliance, pump events, and step count for the previous day or any period • Data is stored on a ‘cloud based’ HIPAA compliant, real-time database, using the Legacy IPC Gateway system. Clinicians can then review data at any time using either the secure portal or the hospital EHR system • The Legacy system supports the tracking of devices, which mitigates the risk of ‘lost devices’ and supports inventory control LEGACY IPC KIT CONNECTED SOFTWARE CHARGING IPC SYSTEM
12 Legacy IPC system An all-in-one IPC solution, ready to go straight out of the box, complemented by a versatile set of peripherals that complete the system Legacy IPC The kit • Legacy comes as a complete kit, which includes the following items: • Legacy IPC Pump x 2 • Legacy bladder (Left/Right) • Legacy comfort sleeve (Left/Right) • Power supply x 1 • Dual USB power lead x 1 • Legacy instruction manual x 1 • The ‘one size fits all’ comfort sleeves provide a light, compliant, and breathable outer shell that delivers maximum patient comfort even when worn for the minimum recommended daily wear of 18 hours • Pumps and bladders are reusable, however the ‘single patient comfort sleeve’ is disposable and sold in packs of 10. It is expected that over the course of a year, over 50 comfort sleeves will be purchased for each Legacy kit Unboxing the Legacy IPC kit Scan QR code
13 Legacy IPC system Legacy IPC…a clear disruptor in intermittent pneumatic compression therapy…globally Software App and Portal • The Legacy Mobile APP with wireless connectivity allows any iOS or Android device to connect to multiple devices to monitor and record the status. • The Legacy Portal allows secure viewing of the real time HIPAA compliant database • Secure patient log-in • Pump status: leak, blockage, battery life, events • Multiple device connection –traffic light system • Compliance log • Steps, cadence, and overall patient activity monitoring • Geo location • Pump lifetime: total cycles / runtime, temperature • Remote pump monitoring for faults and status Connected Monitoring station • Range 150 yards removes the need for repeaters • Single point compliance and record • Remote alarm and event log allows for patient rest • 100 pumps can be recorded at any one time • Remote pump status and details • Compact design using iPad • Clear user interface and control • Secure registration Charging Hub and mini-dock • Easy connection through a ‘push-in’ docking connection • Convenient and organised and accommodates up to 20 (hub) or 2 (mini-dock) Legacy pumps charging at the same time • Compact designs • Safety in use from minimising leads and mitigating the potential for trips and falls • Single point connection through one, sole mains connection • Robust design and manufacture that prevents possible damage to the Legacy Pump from multiple leads
14 Legacy IPC system Unlike other IPC devices, Legacy IPC Gateway qualifies for reimbursement in the U.S. under Remote Patient Monitoring CPT codes — giving hospitals a unique opportunity to generate added revenue through Medicare’s value-based care programme Legacy IPC Gateway Gateway The Legacy IPC Gateway is a patented device that works alongside the Legacy IPC system to securely capture and store real time device data in the cloud • Legacy IPC Gateway monitors as standard: • Air quality; • Air pressure; • Humidity; • Ambient temperature; • Treatment sessions and timing; • Battery life and pump operations; and • Missing devices • All data is securely available online and viewed using the Legacy Portal, with clear graphical displays that make trends easy to track and understand • Legacy IPC Gateway is a compact, plug-in device which is reliable and easy to use and provides a consistent connection by automatically selecting Wi-Fi or Cellular networks • The Legacy IPC Gateway can integrate with a host of medically approved devices to form a comprehensive, cloud-based ecosystem for clinicians enabling ‘remote patient monitoring for ‘Care at Home’ programmes
15 Legacy IPC system Legacy IPC combines breakthrough innovation with real-world practicality, securing its place as a frontrunner in the IPC market as healthcare accelerates its move towards home-based care, digital monitoring, and sustainable solutions Key strengths of Lightweight, silent operation & fully wireless • Unlike traditional bulky hospital IPC systems, Legacy is silent and discreet—ideal for home use, overnight wear, and patient mobility • No need for wall power or bedside equipment— removes a major barrier to compliance both in the home or hospital App-based adherence tracking & remote monitoring • Built-in compliance tracker that sends data to a mobile app or secure database, which can be viewed by both the patient and healthcare team • Enables clinicians to confirm patients are using the device correctly; which in turn solves a long-standing problem associated with IPC adherence and supports better outcomes and value-based reimbursement Eco-friendly: reusable components & a low carbon footprint • Legacy’s pump and bladder are fully reusable, which effectively reduces plastic waste and lowers long-term cost • Compared to traditional hospital IPC systems, Legacy is considerably superior as it aligns with ‘Net Zero goals’ and ‘sustainability standards’ Hospital, outpatient & home-based recovery • Can be used in acute care settings e.g. surgery wards, or as an outpatient for home-based recovery • Legacy is neatly aligned with the trend toward early discharge and increasing preference for remote recovery management Clinical relevance • Reduction of DVT through better compliance over SCDs both in the hospital and home • Recorded compliance rates >85% exceeding guidelines of 75% for clinical effectiveness and typical SCD compliance of 47% Supports the priorities and dynamics of healthcare systems globally • DVT prevention, home care expansion, digital health integration, and sustainability • Legacy aligns with international trends relating to aging populations, postop care at home, and a rising demand for portable devices User and clinician endorsement • Positive testimonials from users emphasise comfort, ease of use, and mobility as the biggest driver for change to Legacy • Clinicians appreciate the compliance data for clinical decision-making and reporting Commercial & financial upside • Meets the needs of cost-conscious healthcare systems (via 1 system for hospital and home), clinicians (via better outcomes), and patients (via higher compliance) • Legacy is a strong value proposition for distributors, rehabilitation centres, and telehealth platforms Clinically targeted for VTE prevention Digital compliance monitoring Hospital & home use Portable, patient friendly design Strong product / market fit High user satisfaction Commercial appeal Environmentally sustainable
16 Legacy IPC system Approvals, endorsements, awards and accreditations…an ever-increasing list of progress and successful clinical validation 2024 2025 FDA approval Regulatory approval received from the FDA 2026 SFDA approval Regulatory approval received from the SFDA Trials Second Mayo Clinic trial Trials First Mayo Clinic trial MedTech Accelerator Award Selected for participation in the prestigious MedTech Accelerator programme Vizient Award Winner of the Vizient Innovative Technology Award MedTech Accelerator Award Winner of the Mayo ASU MedTech Impact Award Trials Mayo Clinic Phoenix trials International standard ISO 13485:2016 recognition Digital health accreditation Received ORCHA Certification Innovation & Excellence Award Winner of the Corporate LiveWire Innovation & Excellence Award “...completely silent whilst running. A real game changer.” Sandra Forde Trials at the Mayo Clinic have shown compliance levels >85% and reported no incidence of VTE. Based on these results Legacy is commencing Mayo’s ACH program in Autumn 2025 Patent award Fully granted patent awarded – GB 2612313A Nursing staff don’t like the current systems as they significantly increase workload and cause patient dissatisfaction Rising patient preference and a systemic shift towards recovery at home creates strong demand for portable, App-connected devices https://news.asu.edu/20250314-health-and-medicineten-companies-five-nations-one-accelerator “...the App is also extremely useful and allows us to track patient compliance with ease.” Kari Golgan 2023 Patent Patent Legacy IPC Gateway – PCT/EP2025/075214
Supply chain
18 Supply chain A thoughtfully designed system with the flexibility to ensure the Legacy system can be made available to healthcare providers and users worldwide Research & development Supply partners • A culture of R&D and a strong emphasis on developing a market-relevant, scalable, and sustainable proposition is evidenced by Legacy’s continual system enhancement • Legacy is not a static proposition. It’s deliberately evolving to ensure that it remains relevant in a dynamic market and can interoperate with contemporary technologies • The Founders apply rigorous development protocols, from ideation and prototyping, through to regulatory testing and deployment. The outcome of this structured and proactive R&D culture is the competitive positioning of the Legacy system and an expansion of its addressable market • Operating from an established base in the UK and running a ‘manufacturing system’ that provides a robust platform for growth • The Founders have developed a process in the UK that can be replicated in overseas locations, whilst still maintaining existing efficiency and quality standards – in particular ISO 13485 • Processes have been designed with portability in mind, enabling rapid setup of international manufacturing hubs thus providing the company with a clear route to scale in global markets • Adopting a multi-channel route to market, comprising direct, GPO and distributor channels • The sales strategy for Legacy has been established to optimise market access, enhance both clinician and patient engagement, and support product deployment across a range of healthcare settings • The company’s distribution framework is designed to scale alongside manufacturing capacity. • As overseas demand grows, the Business can expand its partner network and integrate distribution more directly with localised manufacturing • 1 easily transferable ‘manufacturing system’ • 50 preferred suppliers • 12 critical components • 7 countries of origin • 4 US manufacturers “ready for transfer” Manufacturing Sales UK IG Technology Ltd US IG Technology LLC (Delaware & Arizona)
Growth opportunities
20 Growth opportunities An IPC system with many possibilities - Legacy IPC is perfectly positioned to extend its proven system beyond hospitals…delivering SMART, digitally integrated care into the community Core growth opportunities Expansion into new, emerging markets • The Asia-Pacific region presents a major expansion opportunity for Legacy IPC • In China, the IPC market is growing 10 fold and forecast to reach around $900 million by 2026, driven by a surge in joint replacement surgeries and government efforts to reduce hospital-acquired complications • In India, leading private hospital groups are dedicating 15– 20% of equipment budgets to thrombosis management, reflecting rising DVT incidence and demand for effective compression therapies. Proposition enlargement • Legacy IPC’s development initiatives are closely aligned with user needs, shaped through ongoing collaboration with existing customers, clinicians, and industry partners • Building on this feedback-driven approach, the company is actively developing solutions tailored to high-potential growth segments — including home and communitybased care, and paediatrics • Beyond its core application, Legacy IPC is also being appraised for use in lymphedema management — a space where IPC is a proven therapy and where the shift towards affordable, home-based care presents a substantial growth opportunity Digital health platforms • The Legacy IPC system, through the Legacy Portal and Legacy Gateway, delivers real-time data sharing with healthcare providers and enables seamless EHR integration • Combined with AI-driven analytics and connectivity to other digital health platforms, this capability provides actionable insights, enhances patient monitoring, and supports datadriven decision-making • The Legacy IPC system can be confidently positioned as a fully connected, intelligent solution for modern healthcare delivery
Acquisition drivers
22 Acquisition drivers The Legacy IPC system is a smart acquisition…strategically valuable, low-risk, and positioned to deliver both immediate impact and sustained growth • A game-changing MedTech acquisition that accelerates participation in the connected IPC niche by avoiding costly and prolonged in-house development • Legacy is a regulatoryapproved device, trusted and endorsed by top global healthcare institutions • A fully developed, market-ready system designed for swift scalability without the need for ground-up development • Incorporating a silent pump, reusable elements, and real-time compliance tracking, Legacy provides advanced capabilities that distinguish it from existing market alternatives • By integrating Legacy’s technology, value propositions are elevated with a next-generation IPC solution that is both patient-centric and sustainable • Leveraging Legacy’s patented technologies will serve as a catalyst for advancing technological leadership • A wireless and appenabled portable device, Legacy is optimised for home use, which aligns with the rapid growth of outpatient and remote care models in modern healthcare • Legacy extends hospitalbased performance of IPC devices into a bestin-class, connected system that serves both hospital and homecare environments • Legacy provides a strategic entry point into digital health and remote patient monitoring • Increasing demand for eco-friendly, reusable medical devices aligns with Legacy’s commitment to sustainability • Legacy’s digital compliance tracking supports value-based care models and reimbursement regimes, which are continuing to gain prominence • Opportunity to capture demand fuelled by ageing populations and the growth of home healthcare • Legacy’s compact, easy-to-use design drives higher patient adherence, and reduces VTE events and costs…which is appealing to both payers and providers • With Legacy, new distribution pathways open in outpatient, rehab, and telehealth—fastgrowing markets driving the future of healthcare • Potential to drive incremental growth by cross-selling and bundling Legacy e.g. alongside established surgical and vascular propositions Expansion into connected home / community care IPC Addressing market trends and regulatory drivers Commercial and financial upside Innovation to complement existing portfolios Accelerated time to market and reduced R&D risk • Adds a techforward offering that strengthens differentiation in tenders…which will resonate with the many health systems prioritising digital health and sustainability • Opportunity to not only defend market position but to grow it against incumbents A strengthened competitive position
Appendices 23
Healthcare provider’s needs Legacy IPC Meets…? Silent 1-2dBA over ambient Yes — ideal for sleep and 24h wear Portability / usability for ambulation 106mm x 45mm x 17mm and lightweight @70 grammes Yes — enhances mobility and patient compliance Run-time / daily compliance (18hrs per day) >24hours on a single charge Yes — capability to go beyond ACCP’s daily compliance goal of ~18 hours/day Effectiveness (compression pressure) 45mmHg compression Yes — within therapeutic range for VTE prophylaxis Compliance monitoring / wear-time reporting Wireless connectivity Yes — supports wear-time tracking & documentation Device lifetime / durability One year @ 18Hrs / day Yes — supports sustained, long-term use (e.g. post-op, oncology, community) Versatility (use settings) Hospital or home/community care Yes — aligns with guidelines for both inpatient and outpatient prophylaxis One size fits all Single SKU design Yes — simplifies clinical use and stock management Cost effectiveness 50% reduction in running costs Vs Flowtron / Kendall SCD Yes — supports broader implementation and accessibility Environmental sustainability 66% reduction in plastic waste Vs traditional devices Bonus — supports institutional sustainability goals 24 Appendix 1: Legacy and healthcare providers How the Legacy IPC meets healthcare provider’s needs Legacy IPC meets, and in some areas exceeds, the needs of healthcare providers for effective mechanical VTE prophylaxis. It supports high compliance, silent operation, validated compression strength, real-time monitoring, and both hospital and home use — making it well-suited for a wide range of VTE prevention scenarios “…We recommend the use of only portable, battery-powered IPC devices capable of daily recording and reporting proper wear time. Efforts should be made to achieve 18 hrs. of daily compliance.” ACCP Guidelines
25 Appendix 2: Florida bill on VTEs The Emily Adkins Family Protection Act: statewide legislation that has the potential to change the US landscape for the prevention and management of VTE How Legacy IPC helps to meet key requirements ▪ Easier device use can reduce training burden and improve compliance; data connectivity allows auditing usage, which may support compliance checks or quality metrics ▪ A portable, reliable mechanical option makes it easier to implement prevention protocols especially when pharmacologic prophylaxis is delayed or unsafe ▪ Legacy helps facilities provide more accurate data to registries / AHCA reports, fulfilling the “treatment” or “prevention” metrics expected ▪ Because Legacy supports continuous wear, comfort, and monitoring, it helps ensure therapy is truly delivered (not just prescribed) which improves outcomes What does Florida’s bill mean for the rest of the US? VTE may become a national patient safety priority • Florida is the first state to legislate mandatory VTE risk assessment at admission in certain care settings. Other states may pass similar bills e.g. Mississippi Hospitals will face pressure to formalise VTE protocols • The Florida bill mandates the use of a nationally recognised VTE risk tool and appropriate treatment protocols. Even outside Florida, national hospital chains and accreditation bodies may impose similar measures Rise in use of mechanical prophylaxis (IPC) • Hospitals across the US may re-evaluate their mechanical prophylaxis offerings to ensure they meet compliance and patient adherence goals…with portable IPC devices becoming standard Compliance and data monitoring will be more important • Devices that can track wear-time and transmit data will be favoured. Providers need to demonstrate not just that prophylaxis was prescribed but that it was used More focus on outpatient / post-discharge VTE risk • VTE risk doesn’t end at hospital discharge; many VTEs occur after patients leave hospital. Portable, long-duration prophylaxis options (i.e. battery-powered IPC) will play a larger role in post-discharge protocols Key requirements of Florida’s bill on VTEs Risk assessment on admission • On patient admission, licensed healthcare facilities must perform a VTE risk assessment using a nationally-recognised risk tool Staff Training • Healthcare facilities must train staff in recognising risk factors, signs and symptoms of blood clots, DVT, PE and have response protocols Protocols and policies • Facilities must have protocols for treating patients at risk of VTEs i.e. screening, prevention and treatment measures Registry and reporting • A statewide registry must be established / contracted in order to track VTE incidence. Hospitals, ambulatory surgical centres etc. must report specified data Appropriate medical attention / treatment • For patients who are identified at-risk, facilities are required to provide ‘appropriate medical attention’ for those risks; with the prevention method being ‘evidence based’ and commensurate with risk Legacy IPC is well suited to help institutions comply with Florida’s VTE legislation, as well as any changes to ‘federal policy’ due to its features addressing many of the bill’s implicit and explicit expectations
26 Appendix 3: Glossary ACCP American College of Chest Physicians ACH Advanced Care at Home AHCA Florida Agency for Healthcare Administration AI Artificial intelligence ASU Arizona State University Business IG Technology Ltd CPT Current Procedural Terminology – standardised medical billing code DVT Deep Vein Thrombosis EBITDA Earnings before interest, tax, depreciation and amortisation EHR Electronic Healthcare Records EPIC EPIC Systems Corporation: EHR system Founders Ivan Green, Dr Stephen Ingram, Eliot Clare GPO Group purchasing organisation HIPAA Health Insurance Portability and Accountability Act of 1996 IGT IG Technology Ltd IoT Internet of Things IoMT Internet of Medical Things IPC Intermittent Pneumatic Compression LMWH Low Molecular Weight Heparin LoRa Long range wireless communication technology for low power long-distance data transmission. Suited to IoT applications ORCHA Organisation for the Review of Care & Health Applications PE Pulmonary Embolism SCD Sequential compression device SKU Stock keeping unit VA Veterans Administration VTE Venous Thromboembolism
© Mazars 2020 Contact Praestantia Advisory A Breeze Corporate Finance Limited Partner Practice Mark Day M&A Partner T: +44 (0)7769 661 283 E: mark.day@breezecf.co.uk
flippingbook.comRkJQdWJsaXNoZXIy NTI5NzM=